Kyverna Targets 1H 2026 BLA for Stiff Person Syndrome Drug After Landmark Trial Data; Cash Secured into 2028
summarizeSummary
Kyverna Therapeutics announced strong fourth quarter and full year 2025 financial results, reporting $279 million in cash and equivalents, providing an expected runway into 2028. This financial stability supports key upcoming milestones, including the anticipated Biologics License Application (BLA) submission in the first half of 2026 for miv-cel in Stiff Person Syndrome (SPS). The company highlighted landmark topline data for miv-cel in SPS, demonstrating highly statistically significant clinical benefit and disability reversal, positioning it as a potential first-to-market autoimmune CAR T therapy. Additionally, Kyverna reported positive interim Phase 2 data for miv-cel in generalized myasthenia gravis (gMG) and promising early-stage data in progressive multiple sclerosis (PMS). This comprehensive update signals significant progress across its pipeline and a clear path to commercialization for its lead asset, which is highly material for the company's valuation. Investors will be watching for the BLA submission and further clinical data readouts.
At the time of this announcement, KYTX was trading at $8.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $458.7M. The 52-week trading range was $1.78 to $13.67. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.